REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Intodna S.A. (Poland)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)
Secondary Activities: Support Activities for Animal Production | Pharmaceutical Preparation Manufacturing | All Other Miscellaneous Chemical Product and Preparation Manufacturing | Other Miscellaneous Nondurable Goods Merchant Wholesalers | Rental and Leasing Services | Scientific Research and Development Services | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | All Other Professional, Scientific, and Technical Services | All Other Miscellaneous Ambulatory Health Care Services
Full name: Intodna S.A. Profile Updated: May 14, 2024
Buy our report for this company USD 19.99 Most recent financial data: 2023 Available in: English & Polish Download a sample report

Intodna S.A. is based in Poland. The head office is in Krakow. The company operates in the Research and Development in Biotechnology (except Nanobiotechnology) industry. It was first established on December 31, 2020. From the latest financial highlights, Intodna S.A. reported a net sales revenue increase of 72.92% in 2023. Its’ total assets recorded a growth of 6.88%.

Headquarters
Ul. Profesora Michala Bobrzynskiego 14
Krakow; Malopolskie; Postal Code: 30-348

Contact Details: Purchase the Intodna S.A. report to view the information.

Website: http://wwwintodna.com

Basic Information
Outstanding Shares:
Purchase the Intodna S.A. report to view the information.
Registered Capital:
Purchase the Intodna S.A. report to view the information.
Incorporation Date:
December 31, 2020
Key Executives
Purchase this report to view the information.
President
Purchase this report to view the information.
Management Board Member
Purchase this report to view the information.
Management Board Member
Purchase this report to view the information.
Supervisory Board Member
Purchase this report to view the information.
Supervisory Board Member
Company Performance
Financial values in the chart are available after Intodna S.A. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
72.92%▲
Total operating revenue
77.53%▲
Operating profit (EBIT)
-99.45%▼
EBITDA
-65.54%▼
Net Profit (Loss) for the Period
N/A
Total assets
6.88%▲
Total equity
11.93%▲
Operating Profit Margin (ROS)
-32.26%▼
Net Profit Margin
N/A
Return on Equity (ROE)
N/A
Debt to Equity Ratio
-16.58%▼
Quick Ratio
0.14%▲

Similar companies

Selvita S.A.
 
"Novo Nordisk Pharma" Sp. z o.o.
Celon S.A.
 
Mabion S.A.
Sartorius Stedim Poland Sp. z o.o.
 
Polpharma Biologics S.A.
Explorna Therapeutics Sp. z o.o.
 
Vaxican Sp. z o.o.
Bs Biotechna S.A.
 
Napiferyn Biotech Sp. z o.o.
Famicordtx S.A.
 

To view more information, Request a demonstration of the EMIS service

USD 19.99
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo